Submission timeline: September 11, 2019 (open) - November 8, 2019 (deadline)
For questions, please contact Rebecca Gavin, DF/HCC Development Office at Rebecca_Gavin@dfci.harvard.edu
Eligible sites: Fred Hutchinson Cancer Research Center; Harvard University (Dana-Farber/Harvard Cancer Center members only); MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of California, San Francisco; University of Pennsylvania; Washington University, St. Louis; Wistar Institute
The Emerson Collective Cancer Research Fund is requesting individual or team proposals for research projects related, but not limited to, immunotherapy, metabolic therapies, early detection advancements, ‘high risk/high reward’ initiatives and/or -omic approaches cancer and drug development. Positive criteria include the potential of a project to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer.
This RFA is open to all faculty and trainees sponsored by faculty undertaking research relevant to cancer at the eligible sites. Awards range from 1 to 2 years, $50,000 minimum to $200,000 maximum, which must include both direct and indirect costs. Emerson Collective and associates will evaluate applications on the following positive criteria:
- The audacity and innovation of the research proposal
- The potential of the proposed research to affect multiple cancer types
- The potential to translate said research into further experiments, and clinical trials
- The applicant’s lack of resources to pursue the proposed research
- Compliance with a two-year maximum timeframe for research
Please note: The applicant’s prior experimental track record will not be the principal determining factor in evaluation. This fund does not support incremental research. Emerson Collective evaluates the applicant’s current and pending support. Duplication of proposed science is grounds for Emerson Collective to return the proposal without review.